carbamates has been researched along with Aura in 66 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since 1955, several alkyl-carbamates have been developed for the treatment of anxiety and epilepsy, including meprobamate, flupirtine, felbamate, retigabine, carisbamate, and cenobamate." | 9.12 | The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ? ( Löscher, W; Sills, GJ; White, HS, 2021) |
| "reduction in 28-day total partial seizure frequency of ≥50%) than placebo during both the 12-week maintenance period and the entire 16- or 18-week double-blind phase (i." | 6.47 | Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. ( Deeks, ED, 2011) |
| "Since 1955, several alkyl-carbamates have been developed for the treatment of anxiety and epilepsy, including meprobamate, flupirtine, felbamate, retigabine, carisbamate, and cenobamate." | 5.12 | The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ? ( Löscher, W; Sills, GJ; White, HS, 2021) |
| " The three most recently approved drugs, the so-called third-generation AEDs, include lacosamide, retigabine and eslicarbazepine acetate and are licensed as adjunctive treatment of partial epilepsy in adults." | 4.88 | Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. ( Berry, DJ; Patsalos, PN, 2012) |
| " Food and Drug Administration approved Potiga (ezogabine) as an add-on medication for the treatment of seizures in adults, and it is being developed by Valeant Pharmaceuticals." | 4.88 | ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine). ( Hopkins, CR, 2012) |
| " This compound was effective in delaying onset of PTZ-evoked seizures at the dose of 5mg/kg in kindled animals and significantly reduced oxidative stress better than standard drug phenobarbital (PB)." | 3.81 | Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents. ( Kumari, S; Mishra, CB; Tiwari, M, 2015) |
| " Using a conditional transgenic mouse model, selective ablation of adult neural stem and progenitor cells in the subventricular zone induced a dramatic increase in morbidity and mortality of central nervous system disorders characterized by excitotoxicity-induced cell death accompanied by reactive inflammation, such as 4-aminopyridine-induced epilepsy and ischaemic stroke." | 3.78 | Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity. ( Bacigaluppi, M; Bari, M; Brambilla, E; Butti, E; Cambiaghi, M; Cebrian Silla, A; Centonze, D; Comi, G; D'Adamo, P; De Ceglia, R; De Chiara, V; Garcia-Verdugo, JM; Leocani, L; Maccarrone, M; Martino, G; Musella, A; Muzio, L; Quattrini, A; Rossi, S; Teneud, L, 2012) |
| " Carisbamate reduced the frequency of spontaneous motor seizures in a dose-dependent manner, and was more effective than topiramate at reducing seizures in rats with kainate-induced epilepsy." | 3.74 | A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy. ( Dudek, FE; Grabenstatter, HL, 2008) |
| "Adults with uncontrolled focal seizures despite treatment with 1-3 antiepileptic drugs/antiseizure medications (AEDs/ASMs) were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg once daily." | 3.01 | Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study. ( Ferrari, L; Nisman, A; Rosenfeld, WE, 2021) |
| " Consequently, the aim of the current study was to comparatively evaluate the pharmacokinetic (PK) and pharmacodynamic (PD anticonvulsant activity) profile of EMC and IPC individual enantiomers." | 2.79 | Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ( Bialer, M; Finnell, RH; Mawasi, H; McDonough, JH; Shekh-Ahmad, T; Wlodarczyk, BJ; Yavin, E, 2014) |
| "To achieve seizure freedom in such patients with any modified ASD regimen is an exception." | 2.72 | [Cenobamate-a new perspective for epilepsy treatment]. ( Steinhoff, BJ, 2021) |
| "Epilepsy is one of the most common and disabling chronic neurological disorders." | 2.72 | The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. ( Klein, P; Löscher, W, 2021) |
| "The pooled estimated RR to achieve seizure freedom for the cenobamate group in comparison with placebo was 3." | 2.66 | Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis. ( Brigo, F; Del Giovane, C; Lattanzi, S; Silvestrini, M; Striano, P; Trinka, E; Zaccara, G, 2020) |
| "Ezogabine (D-23129) is a recently approved antiepileptic drug approved by USFDA for adjunctive therapy of partial onset seizures." | 2.49 | Ezogabine: development and role in the management of epileptic seizures. ( Kumar, M; Kumar, R; Verma, A, 2013) |
| "Epilepsy is a serious and common chronic neurological disease with an urgent need for novel treatment options, because 30% of all epilepsy patients do not respond to currently available drugs." | 2.48 | Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. ( Lerche, H; Nies, AT; Orhan, G; Schwab, M; Wuttke, TV, 2012) |
| "reduction in 28-day total partial seizure frequency of ≥50%) than placebo during both the 12-week maintenance period and the entire 16- or 18-week double-blind phase (i." | 2.47 | Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. ( Deeks, ED, 2011) |
| "Eslicarbazepine acetate is a new member of the dibenzazepine family, and blocks the fast inactivated voltage-gated sodium channel." | 2.47 | [New antiepileptic drugs, and therapeutic considerations]. ( Szupera, Z, 2011) |
| "We measured seizure reduction, median reduction in seizure frequency, median dose, responder rate, and treatment-emergent adverse events." | 1.72 | Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study. ( Karkare, S; Kothare, SV; Shah, YD; Varughese, RT, 2022) |
| "Patients with uncontrolled focal seizures despite taking stable doses of 1-3 concomitant antiseizure medications (ASMs) received increasing doses of cenobamate (12." | 1.72 | Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study. ( Abou-Khalil, B; Aboumatar, S; Klein, P; Krauss, GL; Rosenfeld, WE; Sperling, MR, 2022) |
| "Seizures were induced 30 min later using a chemoconvulsant (pentylenetetrazol, PTZ) model, which has been widely used to determine anticonvulsant efficacy of many other antiepileptic drugs in neonatal animals." | 1.38 | Anticonvulsant effect of retigabine during postnatal development in rats. ( Forcelli, PA; Gale, K; Kondratyev, A; Lakhkar, A; Soper, C, 2012) |
| "Female Wistar rats after 90 min of generalized status epilepticus were used." | 1.31 | Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. ( Brandt, C; Ebert, U; Löscher, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (9.09) | 18.7374 |
| 1990's | 5 (7.58) | 18.2507 |
| 2000's | 16 (24.24) | 29.6817 |
| 2010's | 26 (39.39) | 24.3611 |
| 2020's | 13 (19.70) | 2.80 |
| Authors | Studies |
|---|---|
| Specchio, N | 1 |
| Pietrafusa, N | 1 |
| Vigevano, F | 1 |
| Varughese, RT | 1 |
| Shah, YD | 1 |
| Karkare, S | 1 |
| Kothare, SV | 1 |
| Abou-Khalil, B | 1 |
| Aboumatar, S | 1 |
| Klein, P | 2 |
| Krauss, GL | 1 |
| Sperling, MR | 1 |
| Rosenfeld, WE | 2 |
| Ángel Calleja, M | 1 |
| Navarro, A | 1 |
| Serratosa, JM | 1 |
| Toledo, M | 1 |
| Villanueva, V | 1 |
| Subías Labazuy, S | 1 |
| Gil, A | 1 |
| Keam, SJ | 1 |
| Zhao, F | 1 |
| Liu, Y | 1 |
| Dong, H | 1 |
| Feng, S | 1 |
| Shi, G | 1 |
| Lin, L | 1 |
| Tian, Y | 1 |
| Kanyo, R | 1 |
| Wang, CK | 1 |
| Locskai, LF | 1 |
| Li, J | 1 |
| Allison, WT | 1 |
| Kurata, HT | 1 |
| Lattanzi, S | 1 |
| Trinka, E | 1 |
| Zaccara, G | 1 |
| Striano, P | 1 |
| Del Giovane, C | 1 |
| Silvestrini, M | 1 |
| Brigo, F | 1 |
| Soldovieri, MV | 2 |
| Freri, E | 1 |
| Ambrosino, P | 2 |
| Rivolta, I | 1 |
| Mosca, I | 2 |
| Binda, A | 1 |
| Murano, C | 1 |
| Ragona, F | 1 |
| Canafoglia, L | 1 |
| Vannicola, C | 1 |
| Solazzi, R | 1 |
| Granata, T | 1 |
| Castellotti, B | 1 |
| Messina, G | 1 |
| Gellera, C | 1 |
| Labalme, A | 1 |
| Lesca, G | 1 |
| DiFrancesco, JC | 1 |
| Taglialatela, M | 2 |
| Steinhoff, BJ | 1 |
| Löscher, W | 3 |
| Sills, GJ | 1 |
| White, HS | 2 |
| Nisman, A | 1 |
| Ferrari, L | 1 |
| Miceli, F | 1 |
| Manocchio, L | 1 |
| Vanhoof-Villalba, SL | 1 |
| Gautier, NM | 1 |
| Mishra, V | 1 |
| Glasscock, E | 1 |
| Zhou, P | 1 |
| Yu, H | 1 |
| Gu, M | 1 |
| Nan, FJ | 1 |
| Gao, Z | 1 |
| Li, M | 1 |
| Jankovic, S | 1 |
| Ilickovic, I | 1 |
| Hatch, RJ | 1 |
| Reid, CA | 1 |
| Petrou, S | 1 |
| Wehner, T | 1 |
| Chinnasami, S | 1 |
| Novy, J | 1 |
| Bell, GS | 1 |
| Duncan, JS | 1 |
| Sander, JW | 1 |
| Shekh-Ahmad, T | 1 |
| Mawasi, H | 1 |
| McDonough, JH | 1 |
| Finnell, RH | 1 |
| Wlodarczyk, BJ | 1 |
| Yavin, E | 1 |
| Bialer, M | 2 |
| Kumari, S | 1 |
| Mishra, CB | 1 |
| Tiwari, M | 1 |
| Huber, B | 1 |
| Bocchicchio, M | 1 |
| Kalappa, BI | 1 |
| Soh, H | 1 |
| Duignan, KM | 1 |
| Furuya, T | 1 |
| Edwards, S | 1 |
| Tzingounis, AV | 1 |
| Tzounopoulos, T | 1 |
| Smolders, EJ | 1 |
| de Kanter, CT | 1 |
| van 't Veer, N | 1 |
| D'avolio, A | 1 |
| Di Perri, G | 1 |
| Burger, DM | 1 |
| van Wijngaarden, P | 1 |
| Rivera-Arconada, I | 1 |
| Vicente-Baz, J | 1 |
| Lopez-Garcia, JA | 1 |
| Feuerbach, D | 1 |
| Lingenhoehl, K | 1 |
| Olpe, HR | 1 |
| Vassout, A | 1 |
| Gentsch, C | 1 |
| Chaperon, F | 1 |
| Nozulak, J | 1 |
| Enz, A | 1 |
| Bilbe, G | 1 |
| McAllister, K | 1 |
| Hoyer, D | 1 |
| Maljevic, S | 1 |
| Wuttke, TV | 2 |
| Seebohm, G | 1 |
| Lerche, H | 2 |
| Deeks, ED | 1 |
| Szupera, Z | 1 |
| Gunthorpe, MJ | 2 |
| Large, CH | 2 |
| Sankar, R | 3 |
| Sokal, DM | 1 |
| Nehlig, A | 1 |
| Crean, CS | 1 |
| Vanlandingham, KE | 1 |
| Chabwine, JN | 1 |
| Rossetti, AR | 1 |
| Hirt, L | 1 |
| Kuntzer, T | 1 |
| Schluep, M | 1 |
| Michel, P | 1 |
| Démonet, JF | 1 |
| du Pasquier, RA | 1 |
| Vingerhoets, FG | 1 |
| Patsalos, PN | 1 |
| Berry, DJ | 1 |
| Forcelli, PA | 1 |
| Soper, C | 1 |
| Lakhkar, A | 1 |
| Gale, K | 1 |
| Kondratyev, A | 1 |
| Mula, M | 1 |
| Orhan, G | 1 |
| Nies, AT | 1 |
| Schwab, M | 1 |
| Hopkins, CR | 1 |
| Verma, A | 1 |
| Kumar, R | 1 |
| Kumar, M | 1 |
| Butti, E | 1 |
| Bacigaluppi, M | 1 |
| Rossi, S | 1 |
| Cambiaghi, M | 1 |
| Bari, M | 1 |
| Cebrian Silla, A | 1 |
| Brambilla, E | 1 |
| Musella, A | 1 |
| De Ceglia, R | 1 |
| Teneud, L | 1 |
| De Chiara, V | 1 |
| D'Adamo, P | 1 |
| Garcia-Verdugo, JM | 1 |
| Comi, G | 1 |
| Muzio, L | 1 |
| Quattrini, A | 1 |
| Leocani, L | 1 |
| Maccarrone, M | 1 |
| Centonze, D | 1 |
| Martino, G | 1 |
| Ebert, U | 1 |
| Brandt, C | 1 |
| BROUSCHEK, R | 1 |
| FEUERLEIN, W | 1 |
| ABBOTT, JA | 1 |
| SCHOLL, ML | 1 |
| SCHWAB, RS | 1 |
| ENGLAND, AC | 1 |
| DIAMOND, EF | 1 |
| D AMELIO, V | 1 |
| ANNOVI, G | 1 |
| CARTER, CH | 1 |
| Wua, YJ | 1 |
| Dworetzky, SI | 1 |
| Blackburn-Munro, G | 1 |
| Dalby-Brown, W | 1 |
| Mirza, NR | 1 |
| Mikkelsen, JD | 1 |
| Blackburn-Munro, RE | 1 |
| Harrison, PK | 1 |
| Sheridan, RD | 1 |
| Green, AC | 1 |
| Tattersall, JE | 1 |
| Novak, GP | 1 |
| Kelley, M | 1 |
| Zannikos, P | 1 |
| Klein, B | 1 |
| Porter, RJ | 1 |
| Nohria, V | 1 |
| Rundfeldt, C | 5 |
| Kulig, K | 1 |
| Malawska, B | 1 |
| Deshpande, LS | 1 |
| Nagarkatti, N | 1 |
| Ziobro, JM | 1 |
| Sombati, S | 1 |
| DeLorenzo, RJ | 1 |
| Grabenstatter, HL | 1 |
| Dudek, FE | 1 |
| Mazarati, A | 1 |
| Wu, J | 1 |
| Shin, D | 1 |
| Kwon, YS | 1 |
| Dailey, JW | 1 |
| Cheong, JH | 1 |
| Ko, KH | 1 |
| Adams-Curtis, LE | 1 |
| Jobe, PC | 1 |
| Johannessen, SI | 1 |
| Kupferberg, HJ | 1 |
| Levy, RH | 1 |
| Loiseau, P | 1 |
| Perucca, E | 1 |
| Armand, V | 2 |
| Heinemann, U | 2 |
| Thompson, CD | 1 |
| Barthen, MT | 1 |
| Hopper, DW | 1 |
| Miller, TA | 1 |
| Quigg, M | 1 |
| Hudspeth, C | 1 |
| Montouris, G | 1 |
| Marsh, L | 1 |
| Perhach, JL | 1 |
| Sofia, RD | 1 |
| Macdonald, TL | 1 |
| Dost, R | 1 |
| Lawson, K | 1 |
| Cooper, EC | 1 |
| Jannasch, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension[NCT01866111] | Phase 2 | 437 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients achieving a 50% or more reduction from baseline in partial seizure frequency during the double-blind treatment period (NCT01866111)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 23 |
| Cenobamate 100 mg/Day | 44 |
| Cenobamate 200 mg/Day | 63 |
| Cenobamate 400 mg/Day | 67 |
Percent change in complex partial and/or secondarily generalized and/or simple partial motor seizure frequency per 28 days (average 28-day seizure rate) in each treatment group during the double-blind period relative to the pretreatment baseline. (NCT01866111)
Timeframe: baseline and 18 weeks
| Intervention | percent change (Median) |
|---|---|
| Placebo | -24.0 |
| Cenobamate 100 mg/Day | -35.5 |
| Cenobamate 200 mg/Day | -55.0 |
| Cenobamate 400 mg/Day | -55.0 |
23 reviews available for carbamates and Aura
| Article | Year |
|---|---|
Is Cenobamate the Breakthrough We Have Been Wishing for?
Topics: Anticonvulsants; Carbamates; Chlorophenols; Epilepsy; Humans; Seizures; Tetrazoles | 2021 |
Cenobamate: First Approval.
Topics: Administration, Oral; Adult; Anticonvulsants; Carbamates; Chlorophenols; Drug Approval; Epilepsies, | 2020 |
Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Drug Therapy, Combination; Epilepsy; Humans; Rand | 2020 |
[Cenobamate-a new perspective for epilepsy treatment].
Topics: Anticonvulsants; Carbamates; Chlorophenols; Epilepsy; Humans; Seizures; Tetrazoles | 2021 |
The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ?
Topics: Anticonvulsants; Carbamates; Chlorophenols; Epilepsy; Humans; Tetrazoles; Treatment Outcome | 2021 |
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.
Topics: Animals; Anticonvulsants; Bromides; Carbamates; Chlorophenols; Drug Therapy, Combination; Epilepsy; | 2021 |
Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites.
Topics: Animals; Carbamates; Epilepsy; Humans; Indoles; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Me | 2018 |
KV7 channelopathies.
Topics: Animals; Carbamates; Channelopathies; Epilepsy; Humans; KCNQ Potassium Channels; Long QT Syndrome; M | 2010 |
Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy.
Topics: Anticonvulsants; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic | 2011 |
[New antiepileptic drugs, and therapeutic considerations].
Topics: Acetamides; Anticonvulsants; Carbamates; Dibenzazepines; Epilepsy; Humans; Lacosamide; Phenylenediam | 2011 |
The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Phenylenediamines; | 2012 |
Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.
Topics: Acetamides; Anticonvulsants; Carbamates; Dibenzazepines; Drug Interactions; Epilepsy; Humans; Lacosa | 2012 |
Recent and future antiepileptic drugs and their impact on cognition: what can we expect?
Topics: Acetamides; Animals; Anticonvulsants; Carbamates; Cognition; Cognition Disorders; Epilepsy; Forecast | 2012 |
Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.
Topics: Animals; Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Membrane Transport | 2012 |
ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine).
Topics: Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Phenylenediamines; Potassium | 2012 |
Ezogabine: development and role in the management of epileptic seizures.
Topics: Anticonvulsants; Carbamates; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Epilepsy; Hal | 2013 |
Recent developments on KCNQ potassium channel openers.
Topics: Acrylamides; Aminopyridines; Benzamides; Carbamates; Epilepsy; Humans; Indoles; Ion Channel Gating; | 2005 |
Retigabine: chemical synthesis to clinical application.
Topics: Animals; Anticonvulsants; Anxiety; Carbamates; Dose-Response Relationship, Drug; Epilepsy; Humans; K | 2005 |
Carisbamate (RWJ-333369).
Topics: Animals; Anticonvulsants; Carbamates; Clinical Trials as Topic; Epilepsy; Humans | 2007 |
Retigabine.
Topics: Animals; Anticonvulsants; Brain; Carbamates; Clinical Trials as Topic; Epilepsy; Humans; Phenylenedi | 2007 |
Is there a role for potassium channel openers in neuronal ion channel disorders?
Topics: Aminopyridines; Animals; Anticonvulsants; Antihypertensive Agents; Ataxia; Carbamates; Diazoxide; Ep | 2000 |
Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs.
Topics: Animals; Anticonvulsants; Carbamates; Clinical Trials as Topic; Drug Design; Epilepsy; Epilepsy, Ben | 2001 |
[Antiepileptics. 39].
Topics: Acetazolamide; Adrenocorticotropic Hormone; Aminoglutethimide; Anticonvulsants; Barbiturates; Carbam | 1969 |
2 trials available for carbamates and Aura
| Article | Year |
|---|---|
Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; E | 2021 |
Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid.
Topics: Animals; Anticonvulsants; Area Under Curve; Carbamates; Central Nervous System; Convulsants; Disease | 2014 |
41 other studies available for carbamates and Aura
| Article | Year |
|---|---|
Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study.
Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Child; Chlorophenols; Drug Resistant Epilepsy; Epile | 2022 |
Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study.
Topics: Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; Epilepsy | 2022 |
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.
Topics: Adult; Carbamates; Chlorophenols; Cost-Benefit Analysis; Epilepsy; Humans; Lacosamide; Quality-Adjus | 2022 |
An Electrochemophysiological Microarray for Real-Time Monitoring and Quantification of Multiple Ions in the Brain of a Freely Moving Rat.
Topics: Animals; Anticonvulsants; Brain; Calcium; Carbamates; Diamines; Electrochemical Techniques; Epilepsy | 2020 |
Functional and behavioral signatures of Kv7 activator drug subtypes.
Topics: Anilides; Animals; Animals, Genetically Modified; Anticonvulsants; Bridged Bicyclo Compounds; Calciu | 2020 |
Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy.
Topics: Age of Onset; Animals; Anticonvulsants; Carbamates; Cells, Cultured; Child; CHO Cells; Cricetinae; C | 2020 |
Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
Topics: Animals; Anticonvulsants; Atrioventricular Block; Behavior, Animal; Bradycardia; Carbamates; Channel | 2018 |
Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.
Topics: Animals; Anticonvulsants; Carbamates; CHO Cells; Cricetinae; Cricetulus; Epilepsy; KCNQ2 Potassium C | 2013 |
The preclinical discovery and development of ezogabine for the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Carbamates; Drug Discovery; Epilepsy; Humans; Phenylenediamines; Product S | 2013 |
Enhanced in vitro CA1 network activity in a sodium channel β1(C121W) subunit model of genetic epilepsy.
Topics: Action Potentials; Animals; Anticonvulsants; CA1 Region, Hippocampal; Carbamates; Carbamazepine; Dis | 2014 |
Long term retention of retigabine in a cohort of people with drug resistant epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamates; Drug Resistance; Epilepsy; Female; Humans; Lev | 2014 |
Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.
Topics: Animals; Anticonvulsants; Carbamates; Drug Design; Electroshock; Epilepsy; Mice; Pentylenetetrazole; | 2015 |
A retrospective evaluation of retigabine in patients with cognitive impairment with highly drug-resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Cognition; Cognition Disorders; Cohort Studies; Epil | 2015 |
Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
Topics: Animals; Animals, Newborn; Anticonvulsants; Carbamates; Disease Models, Animal; Epilepsy; Evoked Pot | 2015 |
Effective treatment of hepatitis C virus infection with sofosbuvir and daclatasvir 90 mg in a patient with severe epilepsy on oxcarbazepine.
Topics: Anticonvulsants; Antiviral Agents; Carbamates; Carbamazepine; Drug Interactions; Drug Therapy, Combi | 2016 |
Targeting Kv7 channels in pain pathways.
Topics: Aminopyridines; Animals; Carbamates; Deafness; Epilepsy; Humans; Inflammation; KCNQ Potassium Channe | 2017 |
The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
Topics: Acoustic Stimulation; alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Carbam | 2009 |
Deal watch: GSK acquires rights to Valeant's anti-epileptic drug.
Topics: Anticonvulsants; Carbamates; Clinical Trials as Topic; Commerce; Drug Industry; Epilepsy; Legislatio | 2008 |
The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.
Topics: Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Drug Synergism; Epilepsy; Humans; KCNQ | 2012 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brai | 2012 |
Retigabine: fewer drug interactions.
Topics: Anticonvulsants; Carbamates; Drug Interactions; Drug Therapy, Combination; Epilepsy; Humans; Phenyle | 2012 |
Anticonvulsant effect of retigabine during postnatal development in rats.
Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Carbamates; Convulsants; Dose-Response Relationsh | 2012 |
Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity.
Topics: 4-Aminopyridine; Amidohydrolases; Animals; Arachidonic Acids; Benzamides; Carbamates; Corpus Striatu | 2012 |
Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat.
Topics: Animals; Anticonvulsants; Apoptosis; Biomarkers; Carbamates; Caspase Inhibitors; Dizocilpine Maleate | 2002 |
[Valamin therapy in epilepsy].
Topics: Carbamates; Epilepsy; Humans; Hypnotics and Sedatives | 1956 |
A report on the apparent anticonvulsant effect of hydroxyphenamate (Listica).
Topics: Anticonvulsants; Butylene Glycols; Carbamates; Epilepsy; Tranquilizing Agents | 1962 |
An evaluation of AC-601, a new carbamate anticonvulsant, in the therapy of childhood convulsive disorders.
Topics: Anti-Anxiety Agents; Anticonvulsants; Carbamates; Epilepsy; Esters; Humans; Seizures | 1963 |
[TREATMENT WITH MEBUTAMATE (AN ANTIHYPERTENSIVE WITH CENTRAL ACTION) OF MENTAL PATIENTS WITH HYPERTENSIVE MANIFESTATIONS].
Topics: Alcoholism; Antihypertensive Agents; Anxiety; Bipolar Disorder; Carbamates; Dementia; Epilepsy; Huma | 1963 |
EVALUATION OF 2-HYDROXYETHYL-N-BENZYLCARBAMATE IN EPILEPSY.
Topics: Adolescent; Anticonvulsants; Biomedical Research; Carbamates; Child; Epilepsy; Epilepsy, Absence; Ep | 1964 |
Effects of anticonvulsants on soman-induced epileptiform activity in the guinea-pig in vitro hippocampus.
Topics: Amines; Animals; Anticonvulsants; Carbamates; Carbamazepine; Chlormethiazole; Clozapine; Cyclohexane | 2005 |
Carisbamate, a new carbamate for the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Carbamates; Controlled Clinical Trials as Topic; Disease Models, Animal; D | 2007 |
Carisbamate prevents the development and expression of spontaneous recurrent epileptiform discharges and is neuroprotective in cultured hippocampal neurons.
Topics: Action Potentials; Analysis of Variance; Animals; Animals, Newborn; Anticonvulsants; Carbamates; Cel | 2008 |
A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy.
Topics: Analysis of Variance; Animals; Anticonvulsants; Carbamates; Cross-Over Studies; Disease Models, Anim | 2008 |
Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study.
Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Behavior, Animal; Carbamates; Disease Models, Ani | 2008 |
Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response.
Topics: Animals; Anticonvulsants; Carbamates; Dose-Response Relationship, Drug; Epilepsy; Female; Male; Phen | 1995 |
Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference.
Topics: Acetamides; Animals; Anticonvulsants; Azetidines; Carbamates; Drug Evaluation, Preclinical; Drugs, I | 1996 |
Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Bicuculline; Carbamates; Convulsants; Electrophysiology; | 1999 |
Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids.
Topics: Acetylcysteine; Aldehydes; Animals; Anticonvulsants; Carbamates; Chromatography, High Pressure Liqui | 1999 |
Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells.
Topics: Animals; Anticonvulsants; Carbamates; Cells, Cultured; Electrophysiology; Epilepsy; Nerve Growth Fac | 1999 |
The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation.
Topics: Animals; Anticonvulsants; Calcium; Carbamates; Electrophysiology; Epilepsy; gamma-Aminobutyric Acid; | 2000 |
Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices.
Topics: Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Electroencephalography; Entorhinal Cor | 2000 |